Journal of the Korean Ophthalmological Society 2000;41(6):1389-1395.
Published online June 1, 2000.
The Efficacy of Topical 1%Brinzolamide (AzoptTM) as Combined Therapy of beta-blocker for Primary Open Angle Glaucoma and Ocular Hypertension.
Woo Jin Jeung, Dong Yeol Lee, Sae Heun Rho
Department of Ophthalmology, College of Medicine, Dong-A University, Pusan, Korea.
원발 개방각 녹내장과 고안압증 환자에서 1% Brinzolamide ( AzoptTM ) 와 베타차단제의 병용투여 효과 및 미세순환에 미치는 영향
이동열(Dong Yeol Lee),노세현(Sae Heun Rho),정우진(Woo Jin Jeung)
We investigated the effects of 1%brinzolamide on intraocular pressure (IOP)and peripapillary and optic nerve head (ONH)microcirculation with Heidelberg Retina Flowmeter (HRT)in primary open-angle glaucoma (POAG) and ocular hypertension. Primary open-angle glaucoma and ocular hypertension patients (60 eyes 60 person)were divided into 2 groups named A and B.In group A, patients had 1%brinzolamide and beta-blocker (30 eyes 30 person).In group B, patients had beta-blocker only (30 eyes 30 person).IOP and peripapillary and ONH microcirculation were measured before, 1 week, 2 weeks, 1 month, and 3 months after instillation and adverse effects were monitored. In group A, the rate of IOP decrease was 15.5%at 8:00 AM after 1 week of instillation, 17.6%at 4:00 PM after 1 week of instillation, 20.8%at 8:00 AM after 3 months of instillation, 20.8%at 4:00PM after 3 months of instillation, which were statistically significant.The adverse effects were rare including bitter tasting (3 eyes), transient visual disturbance (2 eyes), foreign body sensation (1 eye), etc.But there was no stastically significant change of microcirculation in both groups (P>0.05). We concluded that 1%brinzolamide had good effect for IOP decrease as an adjuvant medication to the beta-blocker.Moreover, long term and further evaluations are considered to be necessary.
Key Words: Brinzolamide;IOP;Peripapillary;ONH microcirculation;Adverse effect

Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail:                

Copyright © 2024 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next